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Background
Aurora kinases are overexpressed and associated with
poor prognosis in several human tumours. Recently, over-
expression and correlation with poor prognosis was found
in canine osteosarcoma. We examined the effects of
Aurora kinase inhibition in canine osteosarcoma cell lines.
This was the first step to explore development of Aurora
kinase inhibitors (AKIs) as novel therapeutic agents for
canine osteosarcoma.
Materials and methods
We evaluated the effects of two AKIs, AZD1152 and
VX680, on four canine osteosarcoma cell lines. Viability
was assessed using the MTS assay, apoptosis using caspase
activation and flow cytometry for Annexin V binding and
7-AAD uptake, and target modulation using Western blot-
ting. We also evaluated gene and protein expression of
Aurora kinase B, ABCB1 and ABG2.
Results
Expression of Aurora kinase B protein and mRNA was seen
in all cell lines. Although Aurora kinase inhibitors induced
cytotoxicity, half-maximal inhibitory concentrations were
significantly higher than seen in other cancer types and
induction of apoptosis was minimal at concentrations close
to IC50s. AZD1152 reduced Aurora kinase B phosphoryla-
tion, indicating effective target modulation. ABCB1 and
ABCG2 transporter-mediated efflux is one known mechan-
ism of resistance against these drugs. Verapamil modestly
enhanced AZD1152-mediated apoptosis and ABC trans-
porters were expressed by a small percentage of cells,
suggesting that other mechanisms may contribute to
resistance.
Conclusions
Canine osteosarcoma cells are resistant to AKIs and we
suggest that these compounds are unlikely to be useful as
monotherapy for this disease. Further investigation of
resistance mechanisms and the potential utility of AKIs in
combination therapy is warranted.
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